Cite

    Wenzel, M. et al. (2021). Assessment of the optimal number of positive biopsy cores to discriminate between cancer‐specific mortality in high‐risk versus very high‐risk prostate cancer patients. Prostate. 81 (14), pp. 1055-1063. [Online].